¼¼°èÀÇ Àü½ÅÈ«¹Ý·çǪ½º ½ÃÀå(2023-2030³â)
Global Systemic Lupus Erythematosus Market - 2023-2030
»óǰÄÚµå : 1279681
¸®¼­Ä¡»ç : DataM Intelligence
¹ßÇàÀÏ : 2023³â 05¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 195 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,350 £Ü 6,294,000
PDF & Excel (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,850 £Ü 7,017,000
PDF & Excel (Multiple User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 7¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,850 £Ü 11,358,000
PDF & Excel (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

½ÃÀå °³¿ä

¼¼°èÀÇ Àü½ÅÈ«¹Ý·çǪ½º ½ÃÀåÀº 2022³â 18¾ï 9,320¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2030³â¿¡´Â 32¾ï 9,570¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Àü½ÅÈ«¹Ý·çǪ½º ½ÃÀåÀº ¿¹Ãø ±â°£(2023-2030³â) Áß 7.3%ÀÇ CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Àü½ÅÈ«¹Ý·çǪ½º(SLE)´Â ¸¸¼º ÀÚ°¡¸é¿ªÁúȯÀ¸·Î, ¸é¿ªÃ¼°è°¡ °Ç°­ÇÑ Á¶Á÷À» À߸ø °ø°ÝÇÏ¿© ÇǺÎ, °üÀý, ½ÅÀå, ½ÉÀå, Æó, ³ú µî¿¡ ÇØ¸¦ ³¢Ä¥ ¼ö ÀÖ´Â ÁúȯÀ¸·Î, ÁÖ·Î ¿©¼º¿¡°Ô ¸¹ÀÌ ¹ß»ýÇÏ¸ç º¸Åë 25¼¼¿¡¼­ 45¼¼ »çÀÌ¿¡ ¹ßº´ÇÕ´Ï´Ù.

Àü½ÅÈ«¹Ý·çǪ½º´Â ¸¸¼ºÀûÀÎ ¿°Áõ°ú ´Ù¾çÇÑ Áõ»óÀ» À¯¹ßÇØ »îÀÇ ÁúÀ» ¶³¾î¶ß¸± ¼ö ÀÖ½À´Ï´Ù. ¼¼°èÀÇ Àü½ÅÈ«¹Ý·çǪ½º ½ÃÀåÀº Áúȯ¿¡ ´ëÇÑ Áö½Ä Áõ°¡, Áø´ÜÀ²ÀÇ Çâ»ó, »õ·Î¿î Ä¡·á¹ýÀÇ ¹ß°ßÀ¸·Î ÀÎÇØ ÇâÈÄ ¸î ³â µ¿¾È Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÃÀå ¿ªÇÐ

Á¤ºÎ ±¸»ó Áõ°¡´Â ¼¼°è Àü½ÅÈ«¹Ý·çǪ½º ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼°è °¢±¹ Á¤ºÎ´Â SLE Ä¡·á¹ý°ú Ä¡·á¹ý¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» ³ôÀ̰í, ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÀçÁ¤Àû Áö¿øÀ» ´Ã¸®¸ç, ȯÀÚµéÀÇ Ä¡·á °á°ú¸¦ °³¼±Çϱâ À§ÇÑ ±ÔÁ¦¸¦ °­È­Çϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù.

¿¹¸¦ µé¾î ¹Ì±¹ Áúº´ÅëÁ¦¿¹¹æ¼¾ÅÍ(CDC)ÀÇ 2022³â º¸°í¼­¿¡ µû¸£¸é CDC-RFA-DP20-2008Àº 5³â°£ÀÇ Çù·Â ÇùÁ¤À» ¸ÎÀº ÀÚ±ÝÁ¶´Þ ±âȸ °ø°í(NOFO)À̸ç, Æó¼âÇüÀÔ´Ï´Ù. ÀÌ Çù·Â ÇùÁ¤ÀÇ ±âº» ¸ñÇ¥´Â ·çǪ½º¿¡ ´ëÇÑ Àνİú ´É·ÂÀ» Çâ»ó½Ã۱â À§ÇØ Àü±¹ÀûÀÎ ³ë·ÂÀ» ±â¿ïÀÌ´Â ±¹³» Á¶Á÷À» Áö¿øÇϰí Çù·Â °ü°è¸¦ ±¸ÃàÇÏ´Â °ÍÀÔ´Ï´Ù.

ÀÌ Çù¾àÀº ·çǪ½ºÀÇ Â¡Èĸ¦ ÀνÄÇÏ°í ¹ß°ß ½Ã ÀûÀýÇÑ ´ëÀÀÀ» ÇÒ ¼ö ÀÖ´Â ÀÇ·áÁøÀ» ´Ã¸®´Â °ÍÀ» ¸ñÇ¥·Î ÇÕ´Ï´Ù. ¶ÇÇÑ ÀÌ ÇùÁ¤Àº ·çǪ½º ȯÀÚÀÇ ÀÚ°¡ °ü¸® Åø¿Í ¼­ºñ½º¿¡ ´ëÇÑ Âü¿©¸¦ Áõ°¡½ÃÄÑ È¯ÀÚÀÇ ÀÚ°¡ °ü¸® ÇൿÀ» ±àÁ¤ÀûÀ¸·Î º¯È­½ÃŰ´Â °ÍÀ» ¸ñÇ¥·Î ÇÕ´Ï´Ù. µû¶ó¼­ À§ÀÇ ¿äÀεéÀº ¿¹Ãø ±â°£ Áß ¼¼°è Àü½ÅÈ«¹Ý·çǪ½º ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼°è Àü½ÅÈ«¹Ý·çǪ½º ½ÃÀåÀº Ä¡·áÀÇ ºÎÀÛ¿ë¿¡ µû¸¥ Á¦¾à¿¡ Á÷¸éÇÒ ¼ö ÀÖ´Ù

±âÁ¸ÀÇ SLE Ä¡·áÁ¦ Áß »ó´ç¼ö´Â ½É°¢ÇÑ ºÎÀÛ¿ëÀ» À¯¹ßÇÒ ¼ö ÀÖÀ¸¸ç, ȯÀÚµéÀÇ »ç¿ëÀ» ¹æÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ȯÀÚµéÀº »ó´çÇÑ ºÎÀÛ¿ëÀÌ ÀÖ´Â Ä¡·á¹ýÀ» äÅÃÇÏ´Â °ÍÀ» ²¨·ÁÇϸç, ÀÌ´Â ½ÃÀå Á¦¾àÀ¸·Î ÀÛ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÇÁ·¹µå´Ï¼ÕÀº ¿°ÁõÀ» ¾ïÁ¦ÇÏ°í °üÀýÅë, ÇǺΠ¹ßÁø µîÀÇ Áõ»óÀ» ¿ÏÈ­ÇÏ´Â µ¥ µµ¿òÀÌ µÇ´Â ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵åÀÇ ÀÏÁ¾ÀÌÁö¸¸, üÁß Áõ°¡, °íÇ÷¾Ð, °ñ´Ù°øÁõ°ú °°Àº ½É°¢ÇÑ ºÎÀÛ¿ëÀÌ ÀÖÀ» ¼ö ÀÖ½À´Ï´Ù.

COVID-19ÀÇ ¿µÇ⠺м®

Äڷγª19ÀÇ À¯Çà°ú ÇÔ²² Àü½ÅÈ«¹Ý·çǪ½º(SLE)°¡ ¼¼°è ½ÃÀå¿¡ Å« ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. SLE ȯÀÚÀÇ ÀÇ·á Á¢±Ù¼º Á¦ÇÑÀº ÆÒµ¥¹ÍÀÇ ½É°¢ÇÑ ¿µÇâ Áß ÇϳªÀ̸ç, ¸¹Àº SLE ȯÀÚµéÀº ¸é¿ª·ÂÀÌ ¾àÇØ Äڷγª19¿¡ °É¸®±â ½±±â ¶§¹®¿¡ ÀÇ·á ±â°üÀ» ã´Â »ç¶÷ÀÌ ÁÙ¾îµé¾î Áúº´À» ¹ß°ßÇϰí Ä¡·áÇÏ´Â µ¥ ½Ã°£ÀÌ °É¸®°Ô µË´Ï´Ù.

Äڷγª19ÀÇ À¯ÇàÀº SLE Ä¡·áÁ¦ ½ÃÀå À¯ÀÔÀ» ¹æÇØÇϰí, ÀÌ·Î ÀÎÇØ SLE Ä¡·áÁ¦°¡ ºÎÁ·ÇØÁ® ȯÀÚ¿Í ÀÇ·á ½Ã½ºÅÛ¿¡ °¡°Ý »ó½ÂÀ¸·Î À̾îÁ® ȯÀÚ °á°ú¿¡ ¾Ç¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù.

·¯½Ã¾Æ-¿ìÅ©¶óÀ̳ª ºÐÀï ºÐ¼®

·¯½Ã¾Æ¿Í ¿ìÅ©¶óÀ̳ªÀÇ ºÐÀïÀº ¼¼°è Àü½ÅÈ«¹Ý·çǪ½º(SLE) ½ÃÀå, ƯÈ÷ SLE Ä¡·áÁ¦ °ø±Þ¸Á¿¡ ÀǵµÇÏÁö ¾ÊÀº °á°ú¸¦ ÃÊ·¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿ìÅ©¶óÀ̳ª´Â ±âŸ ±¹°¡¿¡ ÀǾàǰÀ» ¼öÃâÇÏ´Â Áß¿äÇÑ ÀǾàǰ Á¦Á¶¾÷ü°¡ µÇ°í ÀÖ½À´Ï´Ù. ÀüÀïÀ¸·Î ÀÎÇØ »ý»ê ½Ã¼³°ú ¿î¼Û °æ·Î°¡ ÆÄ±«µÇ°Å³ª Æó¼âµÇ¸é SLE Ä¡·áÁ¦ °ø±Þ¸Á¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù.

¶ÇÇÑ ºÐÀïÀ¸·Î ÀÎÇØ Áö¿ª ³» ÀÇ·á ÀÎÇÁ¶ó¿Í Á¢±Ù¼ºÀÌ ÀúÇÏµÇ¾î ¿ìÅ©¶óÀ̳ª ¹× ÁÖº¯ Áö¿ªÀÇ Àü½ÅÈ«¹Ý·çǪ½º(SLE) ȯÀÚµéÀÌ Áø´Ü°ú Ä¡·á¸¦ À§ÇØ ¿À·£ ½Ã°£ µ¿¾È ±â´Ù·Á¾ß ÇÏ´Â »óȲÀÌ ¹ß»ýÇÒ ¼ö ÀÖ½À´Ï´Ù. ±×·¯³ª ¼¼°è Àü½ÅÈ«¹Ý·çǪ½º ½ÃÀåÀº ´Ù¾çÇϸç, ÀǾàǰ °ø±ÞÀÌ Æ¯Á¤ Áö¿ªÀ̳ª ±¹°¡¿¡ Å©°Ô ÀÇÁ¸ÇÏÁö ¾Ê´Â´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå Á¤ÀÇ¿Í °³¿ä

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå ¿ªÇÐ

Á¦5Àå »ê¾÷ ºÐ¼®

Á¦6Àå COVID-19ÀÇ ºÐ¼®

Á¦7Àå ¾àÁ¦ Ŭ·¡½ºº°

Á¦8Àå µô¸®¹ö¸® ¸ðµåº°

Á¦9Àå À¯Åë ä³Îº°

Á¦10Àå Áö¿ªº°

Á¦11Àå °æÀï ±¸µµ

Á¦12Àå ±â¾÷ °³¿ä

Á¦13Àå ºÎ·Ï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Market Overview

The global systemic lupus erythematosus market reached US$ 1,893.2 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 3,295.7 million by 2030. The systemic lupus erythematosus market is expected to exhibit a CAGR of 7.3% during the forecast period (2023-2030).

Systemic lupus erythematosus (SLE) is a chronic autoimmune condition that can harm the skin, joints, kidneys, heart, lungs, and brain by causing the immune system to wrongly target healthy tissues. SLE is more frequent in women and usually occurs between the ages of 25 and 45.

Chronic inflammation and a variety of symptoms can be caused by the condition, lowering a person's quality of life. The global market for systemic lupus erythematosus is predicted to rise significantly in the next years due to increasing knowledge of the disorder, higher rates of diagnosis, and the discovery of novel therapies.

Market Dynamics

The Rising Number of Government Initiatives is Expected to Drive the Global Systemic Lupus Erythematosus Market Growth.

Governments throughout the world are working to enhance access to SLE treatments and therapies, increase monetary support for R&D, and promote regulations that improve outcomes for patients.

For instance, according to the Centers for Disease Control and Prevention (CDC) 2022 report, the CDC-RFA-DP20-2008 is a closed Notice of Funding Opportunity (NOFO) with a 5-year collaboration agreement. The fundamental goal of this cooperation agreement is to support national organizations in undertaking national initiatives to improve lupus awareness and abilities, as well as to build collaborations.

The goal of this agreement is to increase the number of healthcare practitioners who can recognize lupus signs and take appropriate action if it is detected. Furthermore, the agreement intends to increase lupus patients' participation in self-management tools and services, resulting in a favorable shift in their self-management behaviors. Therefore, the above-mentioned factors, are expected to drive growth of the global systemic lupus erythematosus market over the forecast period.

The Global Systemic Lupus Erythematosus Market May Face Constraints Due to Adverse Effects of Treatment.

Many of the existing SLE therapies have potentially serious side effects, which may prevent patients from using them. Patients may be reluctant to adopt therapies that have considerable adverse effects, which can be a big market restriction.

Prednisone is an example of a corticosteroid that can help reduce inflammation and relieve symptoms like joint pain and skin rashes, but it can also have serious adverse effects including weight gain, high blood pressure, and osteoporosis.

COVID-19 Impact Analysis

In the wake of the COVID-19 epidemic, Systemic Lupus Erythematosus (SLE) has had a substantial influence on the global market. Restricted patient access to medical care has been one of the pandemic's significant effects. Delays in identification and treatment occur as a result of fewer individuals seeking medical attention due to the fact that many SLE patients have compromised immune systems and are more likely to develop severe COVID-19.

This can have a detrimental effect on patient outcomes. The COVID-19 pandemic has also hampered the flow of SLE medications into the market, resulting in shortages and raising prices for patients and healthcare systems.

Russia Ukraine Conflict Analysis

The crisis between Russia and Ukraine may have unintended consequences for the worldwide market for systemic lupus erythematosus (SLE), especially for the SLE drug supply chain. Ukraine is becoming a significant pharmaceutical manufacturer, exporting medicines to other nations. The supply chain for SLE drugs may be affected if production facilities or shipping routes are destroyed or shut down as a result of the war.

In addition, the conflict may result in a decline in the region's healthcare infrastructure and accessibility, which would cause SLE patients in Ukraine and the surrounding territories to wait longer for diagnosis and treatments. The worldwide market for SLE is diversified, nevertheless, and does not rely largely on any one area or nation for the provision of medicines.

Segment Analysis

The global systemic lupus erythematosus market is segmented based on drug class, mode of delivery, distribution channel, and region.

The Hospital Pharmacies Segment is Expected to Dominate the Global Systemic Lupus Erythematosus Market.

The systemic lupus erythematosus (SLE) medication distribution is anticipated to be dominated by hospital pharmacies on a worldwide scale accounting market share of 42.4%. Hospital pharmacies may supply patients with the essential drugs and other therapies and are the main point of care for SLE patients, especially those with severe or complex forms of the condition. Personalised drug dosage and monitoring, as well as access to specialised therapies like intravenous infusions or diagnostic testing, are advantages that hospital pharmacists offer.

Additionally, they already have contacts with healthcare professionals, which makes it simpler to prescribe and monitor drugs as well as to communicate and coordinate treatment. Therefore, owing to the above factors, the hospital pharmacies segment is likely to play major role in accelarating the global systemic lupus erythematosus market growth.

Geographical Analysis

North America Region Holds The Largest Market Share of the Global Systemic Lupus Erythematosus Market.

The global systemic lupus erythematosus market is dominated by North America and holds 1/3rd market share, due to a number of factors, first off, there is more knowledge regarding SLE in this area, which has improved knowledge of the condition and available treatments. Second, compared to other locations, North America has a more established healthcare system, which gives SLE sufferers greater access to medical care and specialised therapies.

In addition, there have been more foundations and independent venture firms funding North American biopharmaceutical producers, which has aided in the creation of novel SLE medications and treatments. For instance, in March 2023, AbbVie revealed the findings of a Phase II research in patients with moderately to highly active systemic lupus erythematosus (SLE) with upadacitinib (RINVOQ, 30 mg) administered alone or in combination treatment (ABBV-599) with a Bruton's Tyrosine Kinase inhibitor (elsubrutinib, 60 mg) once daily.

Competitive Landscape

The major global players in the market include: Anthera Pharmaceuticals, Eli Lilly, GlaxoSmithKline, F. Hoffmann-La Roche, Pfizer Limited, Sanofi, Lycera Corporation, Bristol-Myers Squibb, ImmuPharma Plc, and Merck KGaA.

Why Purchase the Report?

The global systemic lupus erythematosus market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

Table of Contents

1. Methodology and Scope

2. Definition and Overview

3. Executive Summary

4. Dynamics

5. Industry Analysis

6. COVID-19 Analysis

7. By Drug Class

8. By Mode of Delivery

9. By Distribution Channel

10. By Region

11. Competitive Landscape

12. Company Profiles

LIST NOT EXHAUSTIVE

13. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â